A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta-selective agonist in development for the treatment of NASH with liver fibrosis. METHODS: We are conducting an ongoing phase 3 trial involving adults with biopsy-confirmed NASH and a fibrosis stage of F1B, F2, or F3 (stages range from F0 [no fibrosis] to F4 [cirrhosis]). Patients were randomly assigned in a 1:1:1 ratio to receive once-daily resmetirom at a dose of 80 mg or 100 mg or placebo. The two primary end points at week 52 were NASH resolution (including a reduction in the nonalcoholic fatty liver disease [NAFLD] activity score by ≥2 points; scores range from 0 to 8, with higher scores indicating more severe disease) with no worsening of fibrosis, and an improvement (reduction) in fibrosis by at least one stage with no worsening of the NAFLD activity score. RESULTS: Overall, 966 patients formed the primary analysis population (322 in the 80-mg resmetirom group, 323 in the 100-mg resmetirom group, and 321 in the placebo group). NASH resolution with no worsening of fibrosis was achieved in 25.9% of the patients in the 80-mg resmetirom group and 29.9% of those in the 100-mg resmetirom group, as compared with 9.7% of those in the placebo group (P<0.001 for both comparisons with placebo). Fibrosis improvement by at least one stage with no worsening of the NAFLD activity score was achieved in 24.2% of the patients in the 80-mg resmetirom group and 25.9% of those in the 100-mg resmetirom group, as compared with 14.2% of those in the placebo group (P<0.001 for both comparisons with placebo). The change in low-density lipoprotein cholesterol levels from baseline to week 24 was -13.6% in the 80-mg resmetirom group and -16.3% in the 100-mg resmetirom group, as compared with 0.1% in the placebo group (P<0.001 for both comparisons with placebo). Diarrhea and nausea were more frequent with resmetirom than with placebo. The incidence of serious adverse events was similar across trial groups: 10.9% in the 80-mg resmetirom group, 12.7% in the 100-mg resmetirom group, and 11.5% in the placebo group. CONCLUSIONS: Both the 80-mg dose and the 100-mg dose of resmetirom were superior to placebo with respect to NASH resolution and improvement in liver fibrosis by at least one stage. (Funded by Madrigal Pharmaceuticals; MAESTRO-NASH ClinicalTrials.gov number, NCT03900429.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Therefore, incretinbased medications for the treatment of MASLD could be made available, supplementing resmetirom as the only approved medication in the USA and Europe.87”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [87]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Resmetirom is the first compound approved for the treatment of MASH in conjunction with diet and exercise, showing the importance of combining lifestyle changes to pharmacological treatment.91”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [91]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It was not until March 2024 that the U.S. Food and Drug Administration (FDA) approved the first drug, Rezdiffra, for non-alcoholic steatohepatitis (NASH) with liver fibrosis.”
From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Resmetirom, a THRβ agonist, showed antisteatogenic potential in a 36-week phase 2 RCT in people with biopsy-confirmed MASH and fibrosis, accompanied by a rise in circulating adiponectin and improved plasma lipid profile [210,211].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [211]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“About 14% of participants in the MAESTRO-NASH trial were on GLP1RA treatment, with stable dosage in the 6 months and stable body weight in the 3 months preceding screening liver biopsy.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [350]
Experimental — accuracy not yet measured
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationMach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationAlberti, K. G. M. M., Zimmet, P., & Shaw, J. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01858.x · Cited by 6,597
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Self-citationAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Self-citationEstes, C., Razavi, H., Loomba, R., Younossi, Z., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29466 · Cited by 2,399
Self-citationMechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
Self-citation
Research works printed but not linked: 2
- 24. Conduct of clinical trials of medical products during the COVID-19 public health emergency: guidance for industry, investigators, and institutional review boards. Silver Spring, MD: Food and Drug Administration, August 30, 2021 (https:// www . fda . gov/ media/ 136238/ download/ ). Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the
- 3. ogy/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2935-59.
Cited by
Items 701–800 of 1,003
Quercetin in metabolic diseases: mechanisms, therapeutics, and multidimensional frontiers
Song, Q., Liu, L., Yang, Q., Pan, M., & Zhang, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1800322 · Cited by 13
Roeb, E., Canbay, A. E., Bantel, H., Geier, A., Hofmann, W. P., Roden, M., Schattenberg, J. M., Stefan, N., Tacke, F., für die Autoren des DGVS Leitlinienkomitees/for the authors of the DGVS guideline committee, et al. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2769-2397 · Cited by 6
Self-citationAkuta, N., Kogiso, T., Ikejima, K., Otsuka, M., Kawaguchi, T., Kawanaka, M., Takahashi, H., Tamaki, N., Nakagawa, H., 疋田隼人, et al. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-026-02408-2 · Cited by 10
“These include farnesoid X receptor agonists [108] (e.g., obeticholic acid), thyroid hormone receptor-β agonists [109] (e.g., resmeti-rom), and pan-PPAR agonists [110] (e.g., lanifibranor).”
MASLD prevalence, incidence and global aspects
Wild, S. H., Lazarus, J. V., Spearman, C. W., Ocama, P., Bilson, J., Zhou, X., Zheng, M., & Byrne, C. D. (2026) · Diabetologia · doi:10.1007/s00125-026-06726-1 · Cited by 14
“Pharmacological treatments for MASH, including semaglutide, the glucagon-like peptide-1 receptor agonist (GLP-1RA), and resmetirom [67], a selective thyroid hormone receptor-beta (THR-β) agonist, were licensed for the treatment of F2 and F3 liver fibrosis in some high-income countries in 2024 and…”
EASL position paper on preclinical models of steatotic liver disease
Gallage, S., Castro, R. E., Estall, J. L., Tabas, I. A., Anstee, Q. M., TINIAKOS, D. G., Szabó, G., Yu, J., Desdouets, C., Tacke, F., et al. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.04.029 · Cited by 8
Self-citationYodoshi, T., Ollberding, N. J., McNeill, M., Ley, S. L., Kirk, S., Kleiner, D. E., Arce‐Clachar, A. C., Bramlage, K., Inge, T. H., Helmrath, M. A., et al. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70766 · Cited by 7
“…cholesterol; MRE, magnetic resonance elastography; MRI-PDFF, magnetic resonance imaging proton density fat fraction; NAS, NAFLD Activity Score; VSG, vertical sleeve gastrectomy. treatment of MASH with stage 2/3 fibrosis in adults [32], but have not yet been studied in children with MASLD.”
Loomba, R. S., George, J., Castéra, L., Francque, S., Lawitz, E., Shoeb, A., Clausen, J. O., Andersen, B., Larsen, A. B., & Gluud, L. L. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00123-8 · Cited by 9
Self-citationCurrent and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease
Katsarou, A., Tsioulos, G., Kassi, E. N., & Chatzigeorgiou, A. (2024) · HORMONES · doi:10.1007/s42000-024-00588-1 · Cited by 9
“In early 2024, the results from the pivotal phase 3 MAESTRO-NASH Trial (NCT03900429) were published regarding the use of resmetirom in fibrotic NASH patients evaluated by liver biopsy [ 106 , 107].”
Susman, S. J., Santoso, B., & Makary, M. S. (2024) · Biomedicines · doi:10.3390/biomedicines12102226 · Cited by 7
Gao, L., Fang, H., Zhao, Z., Luo, W., Gong, J., & Gong, J. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1486700 · Cited by 7
“Of the more than 400 ongoing clinical trials, only resmetirom has been approved by FDA (8, 9).”
Wentworth, B. J. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.45 · Cited by 8
de Souza, M. H. G., Amaral, M. J. M., Lima, L. C. V., & Villela‐Nogueira, C. A. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18498 · Cited by 6
Mitochondrial targeted therapies in MAFLD
Lai, S., Tang, D., & Feng, J. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151498 · Cited by 11
Le, P. N. B., Kaya, E., Phan, A., Yilmaz, Y., & Alkhouri, N. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000755 · Cited by 13
“[10] Moreover, although resmetirom therapy is associated with a moderate increase in costs, the reduction in expenses related to NASH management underscores its significant cost-effectiveness.”
InfluentialSelf-citationTsuchiya, Y., Nishina, T., Komazawa‐Sakon, S., Seki, T., Mikami, T., & Nakano, H. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150938 · Cited by 5
Single-Cell RNA Sequencing Reveals Macrophage Dynamics During MASH in Leptin-Deficient Rats
Xin, X., Ni, Y., Wang, J., Wu, F., Liu, M., Wu, L. J., Dai, J., Wu, C., Song, X., Zhang, W., et al. (2025) · Cells · doi:10.3390/cells14020096 · Cited by 6
Mullin, S. M., Kelly, A. J., Chathail, M. B. N., Norris, S., Shannon, C. E., & Roche, H. M. (2025) · Advances in Nutrition · doi:10.1016/j.advnut.2025.100375 · Cited by 10
Challenges in Histological Endpoints for MASH Therapies: An Exercise in Statistical Modelling
Shah, A., MacConell, L., Liberman, A., Bisceglie, A. M. D., & Shapiro, D. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70023 · Cited by 5
“While some successful studies have been conducted (e.g., resmetirom, obeticholic acid), they may still be impeded by the imprecision of histologic scoring [25, 26].”
InfluentialNi, D., Qi, Z., Ma, S., Wang, Y., Liang, D., Zhang, X., Man, Y., Chen, J., Dou, K., & Li, G. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102137 · Cited by 5
Polini, B., Ricardi, C., Lupo, F. D., Runfola, M., Bacci, A., Rapposelli, S., Bizzarri, R., Scalese, M., Saponaro, F., & Chiellini, G. (2025) · Cells · doi:10.3390/cells14080580 · Cited by 7
“Among them, resmetirom (Figure 1) was recently approved by the U.S. FDA, under the brand name Rezdiffra™, for treating patients with NASH [28,29], which provides the basis for research and development of new drugs for liver diseases.”
Acetyl-11-keto-β-boswellic acid alleviates hepatic metabolic dysfunction by inhibiting MGLL activity
Luan, K., Fan, Y., Yang, Q., Yang, H., Zhou, Z., Huang, J. W., She, Z., Zou, T., Xiong, H., & Mei, Z. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100812 · Cited by 6
Liu, W., Yao, F., Wang, J.-H., Shao, N., Cao, X., Dong, Z., Zhang, B., & Sun, X. (2025) · Biomedicines · doi:10.3390/biomedicines13061315 · Cited by 8
“Additionally, MASH is a chronic disease, and patients need to take long-term medication, which may increase the risk of adverse reactions [11].”
de Jong, V., Alings, M., Brůha, R., Cortez‐Pinto, H., Dedoussis, G. V., Doukas, M., Francque, S., Fournier, C., Gastaldelli, A., Hankemeier, T., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-092731 · Cited by 8
Self-citationUdaikumar, J., Nimmagadda, R., Lella, V. V., Achuta, K. M., Kuppili, S., Avula, S. R., & Sarwar, R. (2025) · Pharmacoepidemiology · doi:10.3390/pharma4030014 · Cited by 8
Bentanachs, R., Ramírez-Carrasco, P., Braster, B., Emmanouilidou, A., Mújica, E., Rodrigo‐Calvo, M. T., Rodríguez, C., Roglans, N., den Hoed, M., Laguna, J. C., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107860 · Cited by 5
“In this context the recent FDA approval of resmetirom is an important step forward [32].”
Lee, J., Hoon, J., Cho, H. S., Yang, K., Yang, H., Nam, H., Byun, M. Y., Cho, S. K., Park, J., Ko, H. W., et al. (2025) · Journal of Gastroenterology · doi:10.1007/s00535-025-02285-1 · Cited by 10
Li, J., Zhang, D., Liu, P., Fang, R., Li, Y., Zhu, Y., Dong, M., Xie, S., Liu, Y., Wu, J., et al. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120333 · Cited by 10
Henry, D., Baugé, E., Staels, B., & Lalloyer, F. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100086 · Cited by 5
Cui, J., Wang, W., Xu, Q., Zhu, M., Li, Y., Liu, Y., & Liu, Y. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.040775 · Cited by 6
“68 Measures to help improve the prevention of MI in atherosclerosis, such as the use of lipid-lowering medications, are equally beneficial in slowing the progression of MAFLD.”
Kamrul-Hasan, A. B. M., Borozan, S., Jena, S., Nagendra, L., Dutta, D., Bhattacharya, S., Islam, M. S., & Pappachan, J. M. (2025) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v16.i3.110709 · Cited by 7
Mousa, N., Elmetwalli, A., Abdel-Razik, A., Mousa, E., Abdelsalam, M., Elbaz, S., El‐Wakeel, N., Eldars, W., Gad, E., Arafa, M., et al. (2025) · Odontology · doi:10.1007/s10266-025-01184-4 · Cited by 11
“Resmetirom targets the liver and has shown effectiveness in reducing hepatic fat, improving liver health, and reducing biomarkers of liver damage without affecting weight or glucose metabolism [100].”
Wang, T., Duan, L., Zhao, B., Zhang, J., Yu, Y., & Zhao, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1639196 · Cited by 8
Dallio, M., Romeo, M., Nardo, F. D., Senese, G., Silvestrin, A., Coppola, A., Napolitano, C., Vaia, P., Basile, C., Martinelli, G., et al. (2025) · Nutrients · doi:10.3390/nu17213452 · Cited by 6
“In the era of continuously designing new drugs and emerging medications [36–38], lifestyle modification recommendations, including proper dietary habits, continue to represent a cornerstone in the management of MASLD, especially for the relevant proportion of patients without advanced-stage liver…”
Li, D., & Zhang, X. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000846 · Cited by 10
“[156] These promising results prompted the clinical application of Resmetirom.”
Abdelhamed, W., Amin, M. A., Waked, I. A., & El‐Kassas, M. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i45.111643 · Cited by 7
“Resmetirom, a selective thyroid hormone receptor-β agonist, was recently approved by the United States Food and Drug Administration as the first pharmacotherapy for MASH, demonstrating efficacy in reducing hepatic fat and improving fibrosis[133,134].”
Kan, C., Zhang, K., Hou, N., Zheng, T., Sheng, S., Li, X., Han, F., & Sun, X. (2025) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000003087 · Cited by 6
Chen, Y., Yu, H., Kai, X., Yin, R., Ouyang, Z., Wei, Y., & Zhang, C. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117702 · Cited by 6
Convergent Metabolic Pathways in MASH Therapeutics: An AMPK ‐Centric Analysis
Choi, S., Jung, J., Seo, Y., Song, S., Ham, J., Chung, H., Ramadan, Y., & Choi, K. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.71023 · Cited by 6
“Furthermore, fibrosis improvement by at least one stage occurred in 24.2% and 25.9% of the treatment groups, versus 14.2% in the placebo group ( p 0.001) [24].”
InfluentialPοlyzos, S. A., Kountouras, J., Duntas, L. H., & Targher, G. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70507 · Cited by 7
“3 However, the potentially additive effects on related metabolic diseases, especially dyslipidemia, also remain to be demonstrated.”
InfluentialAssessing Nutraceuticals for Hepatic Steatosis: A Standardized In Vitro Approach
Palasantzas, V. E. J. M., Struik, D., Bos, T., Withoff, S., Fu, J., Jonker, J. W., & Hoogerland, J. A. (2026) · Nutrients · doi:10.3390/nu18030388 · Cited by 6
“…[31] HepG2 cultured in DMEM (undefined glucose concentration) and stimulated with 0.5 mM FFA mix of oleic and palmitic acid (2:1) for 24 h Co-treatment for 24 h with 1, 2, 5 * and 10 mM butyrate Intracellular triglyceride concentration, Western blot [29] https://doi.org/10.3390/nu18030388”
InfluentialInduction of TFEB promotes Kupffer cell survival and reduces lipid accumulation in MASLD
Chan, M. M., Daemen, S., Beatty, W. L., Byrnes, K., Cho, K., Ferguson, D., Feldstein, N., Park, C., Guo, Z., Park, A. C., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000853 · Cited by 7
“[4] Therefore, it remains critical to elucidate the cellular and molecular determinants that promote MASLD progression.”
Llach, J., Sòria, A., Graupera, I., & Cardenas, A. (2026) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2026.2632873 · Cited by 5
“Figure 1 It is noteworthy that, over the last 2 years, two pharmacological agents have received the FDA approval for the treat-ment of patients with MASLD without cirrhosis (fibrosis stages F2 and F3) [27,36].”
Ghodrati, F., Zhang, A. B., & Mahmud, N. (2026) · Gastroenterology report · doi:10.1093/gastro/goag006 · Cited by 6
“Its approval was based on phase 3 trial data demonstrating histologic improvement, including resolution of MASH and reduction in fibrosis stage [69].”
Metabolic Dysfunction-Associated Steatotic Liver Disease and Sarcopenia: Review of Literature
Nishikawa, H., Kim, S. K., Yoshio, S., & ASAI, A. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15041661 · Cited by 7
“In 2024, resmetirom, a liver-directed and thyroid hormone receptor beta-selective agonist, was approved by the FDA for the treatment of NASH with liver fibrosis [9].”
Wang, X., Fang, R., Zhao, T., Ding, L., Cai, M., Zhang, D., Xu, N., Yang, S., Zhao, S., Zhang, H., et al. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01400 · Cited by 6
Gougol, A., Kwo, P. Y., Pike, W., Farokhnia, M., Hui, G., Gombar, S., & Mirminachi, B. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70596 · Cited by 9
Athinarayanan, S. J., Wolfberg, A., Shanmugam, P., Hameed, B., & Bonacini, M. (2026) · Hepatology · doi:10.1097/hep.0000000000001713 · Cited by 5
“[14,15,51] Responses to resmetirom appear more pronounced when clinically meaningful weight loss is achieved, [52] underscoring the additive potential of combining pharmacotherapy with structured lifestyle-based care.”
Reinson, T., Bilson, J., Childs, C. E., Buchanan, R. M., Targher, G., & Byrne, C. D. (2026) · BMJ Medicine · doi:10.1136/bmjmed-2025-002038 · Cited by 14
“121 The incidence of serious adverse events was similar across trial groups: 10.9% and 12.7% in the 80 mg and 100 mg resmetirom groups, respectively, and 11.5% in the placebo group.”
InfluentialLiu, M., Ma, Y., Cheang, W. S., Su, Z., & Xu, S. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.04.011 · Cited by 11
Georgakopoulou, V., Steiropoulos, P., Ανδρουτσάκος, Θ., Karabella, I., Reppas, K., Cholongitas, Ε., & Dalamaga, Μ. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00713-8 · Cited by 8
“Resmetirom, a thyroid hormone receptor beta-selective ago - nist, is the first FDA-approved pharmacotherapy for noncir - rhotic MASH with moderate-to-advanced fibrosis (≥ F2), demonstrating significant improvements in both MASH resolution and fibrosis regression in the MAESTRO-NASH trial [65, 66 ].”
Gee, M. F. W., Fonstad, R. K., Vol, E. B. D., Brown, C., Feld, J. J., Patel, K., & Sanyal, A. J. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000000931 · Cited by 6
“[4,10,20] Further, in large phase 3 clinical trials of patients with F2–F3 MASH, baseline ELF values below one standard deviation of the mean were near to 9.00, [38,39] providing supporting evidence for this threshold to detect most patients with F2 fibrosis or higher.”
InfluentialSelf-citationGál, A. R., Szokodi, I., Vizvári, Z., Győrfi, N., Vereczkei, A. G., Petykó, Z., Karádi, Z., & Tóth, A. (2026) · Antioxidants · doi:10.3390/antiox15060710 · Cited by 6
MASLD, diabetes and PMOS across the female life stages
Stener‐Victorin, E., Carlsson, S., Hagström, H., & Taebnia, N. (2026) · Diabetologia · doi:10.1007/s00125-026-06761-y · Cited by 7
“…are approved for MASLD, specifically for individuals with a clinical profile consistent with steatohepatitis and fibrosis stage 2–3: resmetirom, a liver-directed, thyroid hormone receptor β-selective agonist [102], and subcutaneous semaglutide, a glucagon-like peptide-1 receptor agonist [103].”
Statins in Chronic Liver Disease: Review of the Literature and Future Role
Pham, N., & Benhammou, J. N. (2024) · Seminars in Liver Disease · doi:10.1055/a-2319-0694 · Cited by 6
Update on Newly Federal Drug Administration-Approved Drug, Resmetirom: A Practical Perspective
Barritt, A. S., & Stine, J. G. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002922 · Cited by 7
Resmetirom: Breakthrough therapeutic approach for metabolic dysfunction-associated steatohepatitis
Saeed, A., Rai, K. D., & Saeed, M. (2024) · Liver Research · doi:10.1016/j.livres.2024.07.002 · Cited by 5
Noninvasive testing in the diagnosis of metabolic dysfunction-associated steatohepatitis
Marks, L. M., Jensen, T., & DeGrado, T. R. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.44 · Cited by 6
Epicardial and liver fat implications in albuminuria: a retrospective study
Perdomo, C. M., Martín‐Calvo, N., Ezponda, A., Mendoza, F. J., Bastarrika, G., García-Fernández, N., Herrero, J. I., Colina, I., Escalada, J., & Frühbeck, G. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02399-5 · Cited by 6
“The Food and Drug Administration has recently approved resmetirom for the treatment of advanced stages of MASLD [75].”
BackgroundIchikawa, T., Yamashima, M., Yamamichi, S., Koike, M., Nakano, Y., Yajima, H., Miyazaki, O., Ikeda, T., Okamura, T., Komatsu, N., et al. (2024) · Internal Medicine · doi:10.2169/internalmedicine.4337-24 · Cited by 5
“The selective thyroid hormone receptor β agonist (res-metirom) was shown to be superior to placebo in resolving the primary endpoints of NASH without worsening fibrosis and improving fibrosis by at least one stage with no worsening of NASH (12).”
InfluentialAo, N., Du, J., Jin, S., Suo, L., & Yang, J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16043 · Cited by 9
Wang, Y., Shen, L., Wang, C., Dong, Y., Hua, H., Xu, J., Zhang, Y., Huang, H., Huang, Z., Zhao, F., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.11.006 · Cited by 6
Patel, R. H., Parikh, C., Upadhyay, H., Sonaiya, S., Ramnath, P., Singh, S., Patel, U., & Kothari, T. H. (2024) · Cureus · doi:10.7759/cureus.74772 · Cited by 9
Goswami, Y., Baghel, A., Sharma, G., Sharma, P. K., Biswas, S., Yadav, R., Garg, P. K., Shalimar, S., & Tandon, R. (2024) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2024.102463 · Cited by 9
Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction
Kaya, E., Yilmaz, Y., & Alkhouri, N. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2441865 · Cited by 8
“Resmetirom was well tolerated in the phase 3 program safety dataset that included over 2,000 MASLD patients with the main adverse events being nausea and diarrhea [18,19].”
Self-citationNoninvasive Grading of Liver Fibrosis Based on Texture Analysis From MRI‐Derived Radiomics
Gotta, J., Gruenewald, L. D., Reschke, P., Booz, C., Mahmoudi, S., Stieltjes, B., Choi, M. H., D’Angelo, T., Bernatz, S., Vogl, T. J., et al. (2024) · NMR in Biomedicine · doi:10.1002/nbm.5301 · Cited by 7
Misceo, D., Mocciaro, G., D’Amore, S., & Vacca, M. (2024) · Nutrition & Metabolism · doi:10.1186/s12986-024-00871-3 · Cited by 7
“…and hepatic fat content (by enhancing hepatic lipid output), to reduce lipotoxicity, liver enzymes, disease activity and fibrosis despite a neutral effect on body weight or glucose metabolism; it also ameliorated the atherogenic lipid profile with good safety and tolerability [334, 338, 339].”
Koullias, E., Papavdi, M., Koskinas, J. S., Deutsch, M. J., & Thanopoulou, A. C. (2025) · Cureus · doi:10.7759/cureus.76716 · Cited by 13
Pemigatinib suppresses liver fibrosis and subsequent osteodystrophy in mice
Mihara, T., Tsuru, Y., Kurosawa, T., Nonoshita, Y., Yamakawa, Y., & Hori, M. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000610 · Cited by 5
Liu, Y., Zhao, X., Wang, X., & Zhou, Q. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1534628 · Cited by 6
Sheng, Y., Guo, Y., Zhao, B., Mingze, S., Dong, Y., Yin, Y., Wang, Y., Peng, C., Xu, Y., Wang, N., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-07854-x · Cited by 5
Long, L., Wu, Y., Tang, H., Xiao, Y., Wang, M., Shen, L., Shi, Y., Feng, S., Li, C., Lin, J., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-91013-z · Cited by 9
Glutathionylation and metabolic dysfunction-associated steatotic liver disease
Jiang, Z., Chen, L., & Dou, X. (2025) · Biochimie · doi:10.1016/j.biochi.2025.03.006 · Cited by 6
Yang, C.-J., Lin, Y., Wu, H., Yen, C., Lin, C., Kuo, Y., & Chang, H. (2025) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5c00157 · Cited by 5
Bridging the gap: increasing MENA representation in MASLD clinical trials
El‐Kassas, M. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01081-9 · Cited by 6
“Similarly, the phase III trial of res-metirom (NCT03900429) recruited 1,050 patients, of whom 89.3% were of European descent 8 .”
InfluentialOgieuhi, I. J., Olatunji, G. D., Kokori, E., Adeniran, O. F., Awosan, W. R., Kwentoh, I. P., Samuel, O., Ajimotokan, O. I., Okam, O. V., Moradeyo, A. A., et al. (2025) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-025-00468-z · Cited by 6
“These seven studies [34–40] provide promising evidence for resmetirom as a potential treatment for NASH, particularly for patients with liver fibrosis Table 1.”
Galectin-3 inhibition ameliorates hepatic steatosis in a multilineage 3D spheroid model
Sedda, F., Caddeo, A. M., Sasidharan, K., Perra, G., Pal, R. R., Lai, N., Kowalik, M. A., & Perra, A. (2025) · PLoS ONE · doi:10.1371/journal.pone.0326373 · Cited by 5
Chemoprevention of hepatocellular carcinoma using N-acetylgalactosamine-conjugated siRNAs
Maggiore, G., Hsieh, M.-H., Bellary, A., Gopal, P., Li, L., Guo, J., Hsiehchen, D., Dadali, T., Broom, W. J., Maier, M. A., et al. (2025) · Disease Models & Mechanisms · doi:10.1242/dmm.052370 · Cited by 6
Xu, Q., Cao, Z., Yan, H., Xu, L.-L., Liu, Y., Cai, X., & Zheng, Y.-Y. (2025) · ACS Applied Materials and Interfaces · doi:10.1021/acsami.5c10593 · Cited by 7
Recent and anticipated novel drug approvals (Q2 2024 through Q1 2025)
Rim, M. H., Karas, B. L., Barada, F., Dean, C., & Levitsky, A. M. (2024) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxae148 · Cited by 5
Mazhar, S., Azhar, A., Khan, A., Shakil, G., Kumari, S., Devi, D., & Jawad, S. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002314 · Cited by 7
Chitinase 1: a novel therapeutic target in metabolic dysfunction-associated steatohepatitis
Hoon, J., Park, N. R., Cho, S. W., Nam, H., Yang, H., Jung, E. S., Jang, J. W., Choi, J. Y., Yoon, S. K., Sung, P. S., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1444100 · Cited by 7
Kinesin-1 mediates proper ER folding of the CaV1.2 channel and maintains mouse glucose homeostasis
Tanaka, Y., Farkhondeh, A., Yang, W., Ueno, H., Noda, M., & Hirokawa, N. (2024) · EMBO Reports · doi:10.1038/s44319-024-00246-y · Cited by 5
Nidogen 2 Overexpression Promotes Hepatosteatosis and Atherosclerosis
Kathuria, I., Prasad, A., Sharma, B. K., Ofosu‐Boateng, M., Aithabathula, R. V., Gyamfi, M. A., Jiang, J., Park, F., Singh, U. P., & Singla, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312782 · Cited by 6
Paolini, E., Longo, M., Meroni, M., Podini, P., Maggioni, M., Quattrini, A., Fracanzani, A. L., & Dongiovanni, P. (2025) · Antioxidants · doi:10.3390/antiox14060618 · Cited by 7
“Indeed, data from a Phase 3 trial showed that 29% and 25% of patients who received Resmetirom had a resolution of MASH and an improvement of at least one stage of fibrosis, respectively [16], although follow-up studies are required to confirm its efficacy.”
Abeykoon, A. U., Paranagama, M. P., Wijesundera, K. K., Pathirana, O. C., Mahakapuge, T. A. N., & Rajapakse, J. (2025) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-025-04918-7 · Cited by 6
“However, except for Resmetirom which was approved by the FDA in 2024, there are no specific drugs approved for treating MASLD in western medicine [10, 11].”
Celsa, C., Cabibbo, G., & Pinato, D. J. (2024) · Hepatology · doi:10.1097/hep.0000000000001217 · Cited by 5
Implications of liver fibrosis in clinical trials
Jahagirdar, V., Rama, K., Cabrera, D., Idalsoaga, F. J., Díaz, L. A., Arrese, M. A., & Arab, J. P. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.102112 · Cited by 7
Personalized management of metabolic dysfunction-associated steatotic liver disease
Sun, Z., Chan, K. M., & Jin, H. (2025) · iLiver · doi:10.1016/j.iliver.2025.100207 · Cited by 5
Ma, H., Sui, G.-Y., Park, J.-S., Wang, F., Ma, Y., Shin, D.-S., Rustamov, N., Jang, J. S., Chang, S. I., Lee, J., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39534 · Cited by 4
“…Food and Drug Administration approved drug specifically designated for metabolic dysfunction-associated steatohepatitis(MASH) with liver fibrosis [5], yet its scope of action is confined to specific pathways, leaving a substantial unmet need for broader and, more comprehensive therapeutic…”
BackgroundEtemad, A., Tanaka, Y., Wang, S., Slae, M., Sultan, M. I., Elpeleg, O. N., & Hirokawa, N. (2025) · The EMBO Journal · doi:10.1038/s44318-025-00366-8 · Cited by 5
Kehar, M., Huerta‐Saenz, L., Strain, J., Kawesa, S., Yaraskavitch, J., Stine, J. G., & Longmuir, P. E. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-08910-6 · Cited by 4
“While pharmacological treatments like Resmetirom have shown promise in adults [3], no approved therapies exist for children.”
Abbaszadeh, M., Hosseinpanah, F., Tohidi, M., Reyhan, S. K., Mahdavi, M., & Valizadeh, M. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70035 · Cited by 8
Huang, Y., Liu, B., Hu, C., & Lu, Y. (2025) · Protein & Cell · doi:10.1093/procel/pwaf027 · Cited by 6
Targeting CIDEB alleviates liver steatosis and fibrosis in mouse MASH models
Lin, Y., Fan, F., Mo, Z., Huang, Z., Zhou, M., Ma, Y., Qian, C., Wang, Y., Qian, C., & Liu, X. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102567 · Cited by 4
Kumar, S., Lahooti, A., Hajifathalian, K., Critelli, B., Hassan, A., Johnson, K. E., Baig, M. R., Akagbosu, C., Canakis, A., Hassan, K., et al. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-09218-1 · Cited by 4
“…approval followed a phase 3 trial demonstrating superiority over placebo in steatohepatitis resolution and at least one-stage improvement in liver fibrosis; however, it was granted through the accelerated approval program, with ongoing trials still evaluating its efficacy and broader adoption [6].”
Derstine, B. A., Holcombe, S. A., Chen, V. L., Pai, M. P., Sullivan, J. A., Wang, S. C., & Su, G. L. (2025) · Abdominal Radiology · doi:10.1007/s00261-025-05137-x · Cited by 6
“…of hepatic steatosis may be most prominent when there is evidence of moderate-to-severe steatosis (> 15% FF). offer a potential alternative to MR-PDFF for durability of response assessments of emerging therapies like resmetirom to treat metabolic dysfunction-associated fatty liver disease [28].”
Jeong, Y., Oh, A., Jung, Y. H., Jung, K. H., Lee, S., Carrer, M., Lee, S. B., Valenti, L. V. C., Pajvani, U. B., & Kim, K. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01499-w · Cited by 8
New Names, New Drugs, Better Outcomes in Steatotic Liver Disease
Peverelle, M., Mbelle, M., & Joshi, D. (2025) · British Journal of Hospital Medicine · doi:10.12968/hmed.2024.0655 · Cited by 4
Efficacy and Safety of HSK31679 in Asian Patients With MASLD: A Randomized Controlled Trial
Xue, F., Ma, W., Gao, J., Chen, J., Yue, W., Bu, P., Chen, Q., Chen, H., Sheng, J., Liang, C., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.08.009 · Cited by 5
Alkhouri, N., McRae, M. P., Taub, R. A., Hill, B., Imperial, J. C., Kittelson, J., Moussa, S. E., & Everson, G. T. (2025) · Gastro Hep Advances · doi:10.1016/j.gastha.2025.100785 · Cited by 5
Self-citation
Metadata
- Authors
- Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., Anstee, Q. M., Abdelmalek, M. F., Younossi, Z., Baum, S. J., Francque, S., Charlton, M. R., Newsome, P. N., Lanthier, N., Schiefke, I., Mangia, A., Pericàs, J. M., Patil, R., Sanyal, A. J., Noureddin, M., Bansal, M. B., Alkhouri, N., Castera, L., Rudraraju, M., & Ratziu, V.
- Affiliations
- University Hospitals Birmingham NHS Foundation Trust (GB)
- From the University of Oxford, Oxford (S.A.H.), the Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne (Q.M.A.), and the National Institute for Health Research, Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham (P.N.N.) — all in the United Kingdom; Pinnacle Clinical Research, San Antonio (S.A.H., M.R.), South Texas Research Institute, Edinburg (R.P.), and Houston Methodist Hospital, Houston Research Institute, Houston (M.N.) — all in Texas; Liverpat and University of Paris (P.B.), INSERM, Unité Mixte de Recherche Scientifique (UMRS) 1139, Centre de Recherche sur l’Inflammation (L.C.), and Sorbonne Université, ICAN Institute for Cardiometabolism and Nutrition, Assistance Publique–Hôpitaux de Paris (APHP), INSERM, UMRS 1138, Centre de Recherche des Cordeliers (V.R.), Paris, and Université Paris-Cité, Department of Hepatology, Beaujon Hospital, APHP, Clichy (L.C.) — ...
- Universitat Autònoma de Barcelona (ES)
- Houston Methodist (US)
- ORCID
- Harrison, Stephen A.
- Guy, Cynthia D.
- Schattenberg, Jörn M.
- Loomba, Rohit
- Taub, Rebecca
- Neff, Guy W.
- Rinella, Mary E.
- Anstee, Quentin M.
- Abdelmalek, Manal F.
- Younossi, Zobair
- Baum, Seth J.
- Francque, Sven
- Charlton, Michael R.
- Newsome, Philip N.
- Lanthier, Nicolas
- Mangia, Alessandra
- Pericàs, Juan M.
- Patil, Rashmee
- Sanyal, Arun J.
- Noureddin, Mazen
- Bansal, Meena B.
- Alkhouri, Naim
- Rudraraju, Madhavi
- Ratziu, Vlad
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-02-08
- Volume
- 390
- Issue
- 6
- Pages
- 497-509
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4391592880
- Cited by
- 2,084
- References
- 26
- Citations by year
- 2026: 797 · 2025: 807 · 2024: 478
- FWCI
- 635.31
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- Digital Access to Libraries (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Open Access CRIS of the University of Bern
- Funders
- Madrigal Pharmaceuticals
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- resmetirom, nonalcoholic steatohepatitis, liver fibrosis, thyroid hormone receptor beta agonist, NASH resolution, fibrosis regression, NAFLD activity score, LDL cholesterol, triglycerides, cirrhosis prevention, drug safety and tolerability
- MeSH terms
- Adult, Biopsy, Dose-Response Relationship, Drug, Double-Blind Method, Humans, Liver, Liver Cirrhosis, Pyridazines, Uracil, Treatment Outcome, Thyroid Hormone Receptors beta, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.